SELADELPAR



NAME OF DRUG : SELADELPAR

ALSO KNOWN AS : MBX_8025

LABORATORY : CYMABAY_THERAPEUTICS

STATUS AND ADVANCEMENT

Type of drug : PPAR delta receptor agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated time to market : 100 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON SELADELPAR

2019-11-25 : CymaBay Therapeutics Halts Clinical Development of Seladelpar

2019-02-15 : CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

SOME PUBLICATIONS RELATED WITH SELADELPAR

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SELADELPAR


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE